Mari Perez-Rosendahl1, Tahseen Mozaffar1,2,3. 1. Departments of Pathology & Laboratory Medicine. 2. Department of Neurology. 3. The Institute for Immunology, School of Medicine, University of California, Irvine, USA.
Abstract
PURPOSE OF REVIEW: To discuss recent developments in our understanding of epidemiology, diagnostics, biomarkers, pathology, pathogenesis, outcome measures, and therapeutics in inclusion body myositis (IBM). RECENT FINDINGS: Recent epidemiology data confirms a relatively higher prevalence in the population aged above 50 years and the reduced life expectancy. Association with cancer and other systemic disorders is better defined. The role of magnetic resonance imaging (MRI) and ultrasound in diagnosis as well as in following disease progression has been elucidated. There are new blood and imaging biomarkers that show tremendous promise for diagnosis and as outcome measures in therapeutic trials. Improved understanding of the pathogenesis of the disease will lead to better therapeutic interventions, but also highlights the importance to have sensitive and responsive outcome measures that accurately quantitate change. SUMMARY: There are exciting new developments in our understanding of IBM which should lead to improved management and therapeutic options.
PURPOSE OF REVIEW: To discuss recent developments in our understanding of epidemiology, diagnostics, biomarkers, pathology, pathogenesis, outcome measures, and therapeutics in inclusion body myositis (IBM). RECENT FINDINGS: Recent epidemiology data confirms a relatively higher prevalence in the population aged above 50 years and the reduced life expectancy. Association with cancer and other systemic disorders is better defined. The role of magnetic resonance imaging (MRI) and ultrasound in diagnosis as well as in following disease progression has been elucidated. There are new blood and imaging biomarkers that show tremendous promise for diagnosis and as outcome measures in therapeutic trials. Improved understanding of the pathogenesis of the disease will lead to better therapeutic interventions, but also highlights the importance to have sensitive and responsive outcome measures that accurately quantitate change. SUMMARY: There are exciting new developments in our understanding of IBM which should lead to improved management and therapeutic options.
Authors: Jayesh M Pandya; Andreas E R Fasth; Mei Zong; Snjolaug Arnardottir; Lara Dani; Eva Lindroos; Vivianne Malmström; Ingrid E Lundberg Journal: Arthritis Rheum Date: 2010-11
Authors: Steven A Greenberg; Jack L Pinkus; Sek Won Kong; Clare Baecher-Allan; Anthony A Amato; David M Dorfman Journal: Brain Date: 2019-09-01 Impact factor: 13.501
Authors: Lindsay N Alfano; Kendrea L Focht Garand; Georgia A Malandraki; Sharfaraz Salam; Pedro M Machado; Mazen M Dimachkie Journal: Clin Exp Rheumatol Date: 2022-02-07 Impact factor: 4.473
Authors: Anthony A Amato; Michael G Hanna; Pedro M Machado; Umesh A Badrising; Hector Chinoy; Olivier Benveniste; Ananda Krishna Karanam; Min Wu; László B Tankó; Agnes Annette Schubert-Tennigkeit; Dimitris A Papanicolaou; Thomas E Lloyd; Merrilee Needham; Christina Liang; Katrina A Reardon; Marianne de Visser; Dana P Ascherman; Richard J Barohn; Mazen M Dimachkie; James A L Miller; John T Kissel; Björn Oskarsson; Nanette C Joyce; Peter Van den Bergh; Jonathan Baets; Jan L De Bleecker; Chafic Karam; William S David; Massimiliano Mirabella; Sharon P Nations; Hans H Jung; Elena Pegoraro; Lorenzo Maggi; Carmelo Rodolico; Massimiliano Filosto; Aziz I Shaibani; Kumaraswamy Sivakumar; Namita A Goyal; Madoka Mori-Yoshimura; Satoshi Yamashita; Naoki Suzuki; Masashi Aoki; Masahisa Katsuno; Hirokazu Morihata; Kenya Murata; Hiroyuki Nodera; Ichizo Nishino; Carla D Romano; Valerie S L Williams; John Vissing; Lixin Zhang Auberson Journal: Neurology Date: 2021-02-17 Impact factor: 9.910
Authors: J B Lilleker; A Rietveld; S R Pye; K Mariampillai; O Benveniste; M T J Peeters; J A L Miller; M G Hanna; P M Machado; M J Parton; K R Gheorghe; U A Badrising; I E Lundberg; S Sacconi; M K Herbert; N J McHugh; B R F Lecky; C Brierley; D Hilton-Jones; J A Lamb; M E Roberts; R G Cooper; C G J Saris; G J M Pruijn; H Chinoy; B G M van Engelen Journal: Ann Rheum Dis Date: 2017-01-25 Impact factor: 19.103
Authors: Thomas E Lloyd; Iago Pinal-Fernandez; E Harlan Michelle; Lisa Christopher-Stine; Katherine Pak; Ned Sacktor; Andrew L Mammen Journal: Neurology Date: 2017-03-10 Impact factor: 9.910